01 Oct 2025 | 5 Mins Read
Sun Pharma shares rise on Pfizer agreement impact
Flipitmoney
Pfizer agreed to most-favoured-nation pricing with the US Trump administration, reducing Medicaid rates and matching foreign prices with US costs. This aligns with Sun Pharma's specialty portfolio, which accounts for 19% of its sales. Analysts view the deal positively, with little impact on Pfizer's net earnings due to expected rebates, and Sun Pharma shares gained 2.1%.